Ozempic: what the pharmaceutical industry doesn’t want you to know

And what the pharmaceutical industry doesn’t want you to know:

A medication was recently approved by the FDA for the management of diabetes that also causes effortless weight loss. This has led to a surge in demand, even resulting in shortages for diabetic patients.

We're talking about Ozempic (Semaglutide) and similar drugs (Ariana M. Chao et al., 2023).

We are facing a global pandemic of obesity and overweight, with all the inflammatory side effects they bring—effects that seem to be increasingly on the rise.

According to the WHO (2024), 1 in 8 people in the world is living with obesity.

What is Ozempic and what is it used for?‍

It works by mimicking the action of the GLP-1 peptide, a hormone released after eating that helps stimulate insulin secretion. It belongs to the group of hormones called incretins, which help regulate blood sugar levels and also act on the central nervous system to regulate appetite and satiety centers—reducing hunger, making you eat less, and therefore leading to weight loss.

How many kilos can be lost with Ozempic?‍

Statistics show that, on average, about 15% of initial body weight is lost over treatments lasting up to 68 weeks (Ariana M. Chao et al., 2023).
This means that if you weigh 80 kg, you could lose 12 kg, ending up at 68 kg.

If your insurance doesn’t cover it…
Every kilogram you lose with Ozempic could cost you $500 USD!

We know you want to lose weight, that you’ve tried many times, that you’re stuck in that cycle of ups and downs, looking for more tools and thinking this medication might be the solution. But there is no magic pill. This medication is a wildcard.

If you’re considering it or already using it…
Here are its side effects and how to counteract them:

1. Delayed gastric emptying, leading to poor digestion and absorption of nutrients, supplements, and even medications.‍

What you can do: Eat gut-friendly foods that are easy to digest and non-inflammatory. We recommend removing grains, cow’s dairy, and sugars, and personalizing your 3R Protocol.

2. Nausea, gas, and abdominal discomfort.

What you can do: Support your digestion with warm infusions or a bit of warm water with lemon—ideally along with digestive enzymes.

3. Loss of muscle mass, due to reduced protein intake.‍

What you can do: Prioritize protein in every meal according to your personal tolerance. Do strength training, assess your body composition, and monitor that the weight you lose comes from fat, not muscle.

Discover the cause of your inflammation and change your habits! At NutriWhite, we can help you!

You can have a long-lasting alternative for weight loss without rebound through immunonutrition!

At NutriWhite Consultation, we support you through your habit-change process to promote gut health through Immunonutrition.
Learn more about our consultation plans by clicking here.

REFERENCES:

• Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. PMID: 34942372; PMCID: PMC9209591. https://pubmed.ncbi.nlm.nih.gov/34942372/ 
• Christoffersen BØ, Sanchez-Delgado G, John LM, Ryan DH, Raun K, Ravussin E. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity (Silver Spring). 2022 Apr;30(4):841-857. doi: 10.1002/oby.23374. PMID: 35333444; PMCID: PMC9310705.
• Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity Tohru Hira 1,2,3,*, Aphichat Trakooncharoenvit 2, Hayate Taguchi 3 and Hiroshi Hara, 2021
• Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574. PMID: 37796527; PMCID: PMC10557026.
• Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022 Oct 20;10:996179. doi: 10.3389/fpubh.2022.996179. PMID: 36339230; PMCID: PMC9631444. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631444/ 
• Fragozo-Ramos MC. Metabolic syndrome: A literature review. 2022. https://docs.bvsalud.org/biblioref/2022/06/1370951/sindrome-metabolico.pdf 
• León-Pedroza JI, González-Tapia LA, del Olmo-Gil E, Castellanos-Rodríguez D, Escobedo G, González-Chávez A. Low-grade systemic inflammation and its relationship with the development of metabolic diseases: from molecular evidence to clinical application.